Ying Yang

Ying Yang

Auto-generated profile, based on publicly available information

Ying Yang

State Key Laboratory of Frigid Zone Cardiovascular Diseases, Department of Pharmacology, College of Pharmacy, Harbin, Heilongjiang, P.R. China (H.W., Y. Zhuang, Y. Yue, Jiangqi Liu, J.H., Y. Yao, Junwu Liu, Y. Li, Z.Y., Y.W., W.Y., B.M., X.H., Z.T., Y. Yang, Jialiang Li, Y. Zhang, B.Y., Z.P., Y. Lu)

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2025 in Circulation Research
Verified
Journal Article
Closed access
HWHao Wu
Hao Wu
YZYuting Zhuang
Yuting Zhuang
YYYing Yue
Ying Yue
JLJiangqi Liu
Jiangqi Liu
JHJin Han
Jin Han
YLYanjie Lu
Yanjie Lu
BACKGROUND: Disturbance in protein synthesis and degradation plays a crucial role in various biological and pathological processes. E3 ubiquitin ligase substrate–binding adaptor SPOP (speckle-type POZ [poxvirus and zinc finger] protein) is substantially involved in cancer progression. The study aims to investigate the biological function of SPOP in cardiac hypertrophy and heart failure. METHODS: We generated cardiac-specific transgenic and knockout mice to evaluate the functional role of SPOP in transverse aortic constriction–induced cardiac hypertrophy and heart failure. RNA-sequencing, proteomics, and protein mass spectrometry analysis, and multiple molecular biological methodologies were employed to investigate its function and mechanisms in cardiac hypertrophic mice. RESULTS: SPOP was significantly upregulated in human heart failure, hypertrophic mouse hearts, and Ang II (angiotensin II)–treated neonatal mouse ventricular cardiomyocytes. SPOP induced the expression of hypertrophic markers ANP (atrial natriuretic peptide), BNP (B-type natriuretic peptide), and β-MHC (β-myosin heavy chain), increased cardiomyocyte size, whereas SPOP deficiency exhibited the opposite effects in hypertrophic neonatal mouse ventricular cardiomyocytes. Furthermore, cardiac-specific overexpression of SPOP led to cardiac hypertrophy and heart failure in mice. In contrast, cardiac-specific knockout of SPOP markedly attenuated transverse aortic constriction–induced cardiac hypertrophy and improved heart failure. In parallel, SPOP presented prohypertrophic effects, and SPOP loss-of-function substantially rescued Ang II–induced hypertrophic phenotype in neonatal mouse ventricular cardiomyocytes. Mechanistically, SPOP is transcriptionally activated by p300 under cardiac hypertrophy, subsequently interacting with and promoting ubiquitination-mediated degradation of TFEB (transcription factor EB) independently of its phosphorylation status, a key regulator for transcription of lysosomal biogenesis and autophagy-related genes, leading to blockage of autophagy and mitophagy, which eventually causes cardiac hypertrophy and heart failure. Overexpression of TFEB rescued SPOP-induced these alterations. Noticeably, a specific inhibitor of SPOP was able to prevent the development of cardiac hypertrophy and heart failure. CONCLUSIONS: SPOP is a detrimental factor in pathological cardiac hypertrophy via promoting ubiquitination-induced degradation of TFEB, a critical regulator of the autophagy-lysosomal pathway. Targeting SPOP represents a promising therapeutic strategy for hypertrophy-related heart failure.

1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
ZHZhengrong Huang
Zhengrong Huang
ZZZi-Guan Zhang
Zi-Guan Zhang
MCMin-Wei Chen
Min-Wei Chen
YYYing Yang
Ying Yang
RLRun-Jing Li
Run-Jing Li
ZHZhengrong Huang
Zhengrong Huang
The precise control of cardiomyocyte viability is imperative to combat myocardial ischemia‐reperfusion injury (I/R), in which apoptosis and pyroptosis putatively contribute to the process. Recent researches indicated that GSDMD is involved in I/R as an executive protein of pyroptosis. However, its effect on other forms of cell death is unclear. We identified that GSDMD and GSDMD‐N levels were significantly upregulated in the I/R myocardium of mice. Knockout of GSDMD conferred the resistance of the hearts to reperfusion injury in the acute phase of I/R but aggravated reperfusion injury in the chronic phase of I/R. Mechanistically, GSDMD deficiency induced the activation of PARylation and the consumption of NAD+ and ATP, leading to cardiomyocyte apoptosis. Moreover, PJ34, a putative PARP‐1 inhibitor, reduced the myocardial injury caused by GSDMD deficiency. Our results reveal a novel action modality of GSDMD in the regulation of cardiomyocyte death; inhibition of GSDMD activates PARylation, suggesting the multidirectional role of GSDMD in I/R and providing a new theory for clinical treatment.